Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04760431 | TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) | unknown | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04907344 | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 / Phase 3 | 420 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| May 28, 2021 |
| clinicaltrials |
| NCT02185352 | Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases(A-Plus) | unknown | Phase 2 | 120 | National Taiwan University HospitalOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04809779 | PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC(NeoPD1TNBC) | unknown | Phase 2 | 49 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | unknown | Phase 1 / Phase 2 | 132 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04780347 | Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer | unknown | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03698383 | Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 15 | Korean Cancer Study GroupOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04750382 | A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 31 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04736186 | Prevention and Treatment of Pyrrolitinib-associated Diarrhea | unknown | Phase 2 / Phase 3 | 470 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04705909 | Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer | unknown | Phase 2 / Phase 3 | 60 | Mansoura UniversityOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04681911 | Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 71 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04034589 | Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer | unknown | Phase 2 | 46 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04676997 | Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | unknown | Phase 2 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04639271 | Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis | unknown | Phase 2 | 100 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03144947 | Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients(IMMUN-HER) | unknown | Phase 2 | 65 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04580784 | Weekly Single Fraction Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer | unknown | Phase 2 | 20 | Mona SalemOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04571437 | Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)(B-001) | unknown | Phase 2 | 204 | Cairo UniversityOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT04559308 | The Effect of Metformin on Breast Cancer Patients | unknown | Phase 2 | 80 | Beni-Suef UniversityOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT04520386 | OMT-111 for Terminal Stage Solid Tumors | unknown | Phase 2 | 78 | MetiMedi PharmaceuticalsINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04517292 | Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)(GEP) | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04502680 | Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients(EMBRAVE-001) | unknown | Phase 2 | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2020 | clinicaltrials |
| NCT03504865 | Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo | unknown | Phase 2 | 100 | Georgetown UniversityOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03044730 | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT03933319 | Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04387630 | Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer. | unknown | Phase 2 / Phase 3 | 120 | Mansoura UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04073680 | A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Petra PharmaINDUSTRY | 0 | May 21, 2020 | clinicaltrials |
| NCT04158947 | A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone(HER2BAT) | unknown | Phase 2 | 130 | xuexin heOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT04247633 | High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx) | unknown | Phase 2 | 578 | Samsung Medical CenterOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT04302441 | A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy | unknown | Phase 2 | 550 | Fudan UniversityOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01270373 | NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?(NeoSAMBA) | unknown | Phase 2 | 112 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04255056 | Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab(PRETTY) | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04246502 | Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT03994107 | Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | unknown | Phase 1 / Phase 2 | 40 | Peking Union Medical CollegeOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04236310 | A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. | unknown | Phase 2 | 37 | Ruijin HospitalOTHER | 0 | Jan 22, 2020 | clinicaltrials |
| NCT01800422 | Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer | unknown | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT04194684 | Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer | unknown | Phase 2 | 108 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT04001725 | Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases(OPTIMAL) | unknown | Phase 2 | 110 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT04152057 | Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04143906 | Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Oct 30, 2019 | clinicaltrials |
| NCT04094896 | TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer | unknown | Phase 2 | 200 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04095390 | A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer(INPHASE) | unknown | Phase 2 | 60 | Jinming YuOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04088110 | Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | unknown | Phase 2 | 77 | Fuzhou General HospitalOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03638648 | Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy(RSBNAT) | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 0 | Sep 10, 2019 | clinicaltrials |
| NCT02506777 | Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.(MBC1) | unknown | Phase 2 | 96 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02506790 | Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer | unknown | Phase 2 | 96 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT03572361 | Open Label Immunotherapy Trial for Breast Cancer(V3-MOMMO) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2021source: clinicaltrials